1. Shoback, D. (2008). Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391-403.
2. Fisher, N. G., Armitage, A., McGonigle R. J., and Gilbert, T. J. (2001). Hypocalcaemic cardiomyopathy; the relationship between myocardial damage, left ventricular function, calcium and ECG changes in a patient with idiopathic hypocalcaemia. Eur. J. Heart Failure. 3, 373-376.
3. Tziomalos, K., Kakavas, N., Kountana, E., Harsoulis, F., Basayannis, E. (2006). Reversible dilated hypocalcaemic cardiomyopathy in a patient with primary hypoparathyroidism. Clin Endocrinol (Oxf). 64, 717-718.
4. Tomlinson, S., Hendy, G. N., and O'Riordan, J. L. H. (1976). A simplified assessment of response to parathyroid hormone in hypoparathyroid patients. Lancet 1, 62-64.
5. Gidding, S. S., Minciotti, A. L., and Langman, C. B. (1988). Unmasking of hypoparathyroidism in familial partial DiGeorge syndrome by challenge with disodium edetate. N. Engl. J. Med. 319, 1589-1591.
6. Lienhardt, A., Bai, M., Lagarde, J. P., Rigaud, M., Zhang, Z., Jiang, Y., Kottler, M. L., Brown, E. M., and Garabedian, M. (2001). Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J Clin. Endocrinol. Metab. 86, 5313-5323.
7. McKusick, V. (2001). Online Mendelian Inheritance in Man (OMIM). Baltimore: Johns Hopkins University Press.
8. Arnold, A., Horst, S. A., Gardella, T. J., Baba, H., Levine, M. A., and Kronenberg, H. M. (1990). Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J. Clin. Invest. 86, 1084-1087.
9. Datta, R., Waheed, A., Shah, G.N., and Sly, W.S. (2007). Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl. Acad. Sci. USA. 104, 19989-19994.
10. Sunthornthepvarakul, T., Churesigaew, S., and Ngowngarmratana, S. (1999). A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J. Clin. Endocrinol. Metab. 84, 3792-3796.
11. Parkinson, D. B., and Thakker, R. V. (1992). A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat. Genet. 1, 149-152.
12. Nesbit, M.A., Bowl, M.R., Harding, B., et al. (2004). X-linked hypoparathyroidism region on Xq27 is evolutionarily conserved with regions on 3q26 and 13q34 and contains a novel P-type ATPase. Genomics 84, 1060–1070
13. Bowl, M.R., Nesbit, M.A., Harding, B, et al. (2005). An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. J. Clin. Invest. 115, 2822-2831
14. Pollak, M. R., Brown, E. M., Estep, H. L., McLaine, P. N., Kifor, O., Park, J., Hebert, S. C., Seidman, C. E., and Seidman, J. G. (1994). Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nat. Genet. 8, 303-307.
15. Hendy, G. N., D'Souza-Li, L., Yang, B., Canaff, L., and Cole, D. E. (2000). Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 16, 281-296.
16. Cole, D.E.C., Yun, F.H., Wong, B.Y., Shuen, A.Y., Booth, R.A., Scillitani, A., Pidasheva, S., Zhou, X., Canaff, L., and Hendy, G.N. (2009). Calcium-sensing receptor mutations and denaturing high performance liquid chromatography. J. Mol. Endocrinol. 42, 331-339.
17. Hendy, G.N., Guarnieri, V., and Canaff, L. (2009). Calcium-sensing receptor and associated diseases. Prog. Mol. Biol. Transl. Sci. 89C, 31-95.
18. Hendy, G. N., Minutti, C., Canaff, L., Pidasheva, S., Yang, B., Nouhi, Z., Zimmerman, D., Wei, C., and Cole, D. E. (2003). Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 88, 3674-3681.
19. Ray, K., Hauschild, B. C., Steinbach, P. J., Goldsmith, P. K., Hauache, O., and Spiegel, A. M. (1999). Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca2+ receptor critical for dimerization. Implications for function of monomeric Ca2+ receptor. J. Biol. Chem. 274, 27642-27650.
20. Pidasheva, S., D'Souza-Li, L., Canaff, L., Cole, D.E., and Hendy, G.N. (2004). CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 24, 107-111.
21. Kanemura, Y., Hiraga, S., Arita, N., Ohnishi, T., Izumoto, S., Mori, K., Matsumura, H., Yamasaki, M., Fushiki, S., and Yoshimine, T. (1999). Isolation and expression analysis of a novel human homologue of the Drosophila glial cells missing (gcm) gene. FEBS Lett. 442, 151-156.
22. Gunther, T., Chen, Z. F., Kim, J., Priemel, M., Rueger, J. M., Amling, M., Moseley, J. M., Martin, T. J., Anderson, D. J., and Karsenty, G. (2000). Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406, 199-203.
23. Okabe, M., and Graham, A. (2004). The origin of the parathyroid gland. Proc. Natl. Acad. Sci. USA 101, 17716-17719.
24. Ding, C., Buckingham, B., and Levine, M. A. (2001). Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J. Clin. Invest. 108, 1215-1220.
25. Thomee, C., Schubert, S.W., Parma, J., Le, P.Q., Hashemolhosseini, S., Wegner, M., and Abramowicz, M.J. (2005). GCMB mutation in familial isolated hypoparathyroidism with residual secretion of parathyroid hormone. J. Clin. Endocrinol. Metab. 90, 2487-2492.
26. Canaff, L., Zhou, X., Mosesova, I., Cole, D.E.C., and Hendy, G.N. (2009). Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism. Hum. Mutat. 30, 85-92.
27. Bowl, M.R., Mirczuk, S.M., Grigorieva, I.V., Piret, S.E., Cranston. T., Southam, L., Allgrove, J., Bahl, S., Brain, C., Loughlin, J., Mughal, Z., Ryan, F., Shaw, N., Thakker, Y.V., Tiosano, D., Nesbit, M.A., and Thakker, R.V. (2010). Identification and characterization of novel parathyroid-specific transcription factor Glial Cells Missing Homolog B (GCMB) mutations in eight families with autosomal recessive hypoparathyroidism. Hum. Mol. Genet. 19, 2028-2038.
28. Mannstadt, M., Bertrand, G., Muresan, M., Weryha, G., Leheup, B., Pulusani, S.R., Grandchamp, B., Juppner, H., and Silve, C. (2008). Dominant-negative GCMB mutations cause an autosomal dominant form of hypoparathyroidism. J. Clin. Endocrinol. Metab. 93, 3568-3576.
29. Mirczuk, S.M., Bowl, M.R., Nesbit, M.A., Cranston, T., Fratter, C., Allgrove, J., Brain, C., and Thakker, R.V. (2010). A missense glial cells missing homolog B (GCMB) mutation, Asn502His, causes autosomal dominant hypoparathyroidism. J. Clin. Endocrinol. Metab. 95, 3512-3516.
30. Maret, A., Ding, C., Kornfield, S.L., Levine, M.A. (2008). Analysis of the GCM2 gene in isolated hypoparathyroidism: a molecular and biochemical study. J. Clin. Endocrinol. Metab. 93, 1426-1432.
31. DiGeorge, A. M. (1965). Discussions on a new concept of the cellular basis of immunity. J. Pediatr. 67, 907-908.
32. McDonald-McGinn, D.M., and Sullivan, K.E. (2011). Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 90, 1-18.
33. Botto, L. D., May, K., Fernhoff, P. M., Correa, A., Coleman K., Rasmussen, S. A., et al. (2003). A population based study of the 22q11.2 deletion: Phenotype, incidence and contribution to major birth defects in the population. Pediatrics 112, 101-107.
34. Baldini, A. (2004). DiGeorge syndrome: an update. Curr. Opinion Cardiol. 19, 201-204.
35. Huh, S.H., and Ornitz, D.M. (2010). Beta-catenin deficiency causes DiGeorge syndrome-like phenotypes through regulation of Tbx1. Development. 137, 1137-1147.
36. Guo, C., Sun, Y., Zhou, B., Adam, R.M., Li, X., Pu, W.T., Morrow, B.E., Moon, A., Li, X. (2011). A Tbx1-Six1/Eya1-Fgf8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. J. Clin. Invest. 121, 1585-1595.
37. Yagi, H., Furutani, Y., Hamada, H., Sasaki, T., Asakawa, S., Minoshima, S., et al. (2003). Role of TBX1 in human del22q11.2 syndrome. Lancet 362, 1366-1373.
38. Driscoll, D. A., Salvin, J., Sellinger, B., Budarf, M. L., McDonald-McGinn, D. M., Zackai, E. H., and Emanuel, B. S. (1993). Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis. J. Med. Genet. 30, 813-817.
39. Liu, H., Abecasis., G. R., Heath, S., Knowles, A., Demars S., Chen, Y.-J., et al. (2002). Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc. Natl. Acad. Sci. USA 99, 16859-16864.
40. Kapadia, R.K., and Bassett, A.S. (2008). Recognizing a common genetic syndrome: 22q11.2 deletion syndrome. CMAJ. 178, 391-393.
41. Miller, J. D., Bowker, B. M., Cole, D. E.C., and Guyda, H. J. (1983). DiGeorge's syndrome in monozygotic twins. Treatment with calcitriol. Am. J. Dis. Child. 137, 438-440.
42. Goodship, J., Cross, I., Scambler, P., and Burn, J. (1995). Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. J. Med. Genet. 32, 746-748.
43. Hillebrand, G., Siebert, R., Simeoni, E., and Santer, R. (2000). DiGeorge syndrome with discordant phenotype in monozygotic twins. J. Med. Genet. 37, E23.
44. Carelle-Calmels, N., Saugier-Veber, P., Girard-Lemaire, F., Rudolf, G., Doray, B., Guérin, E., Kuhn, P., Arrivé, M., Gilch, C., Schmitt, E., Fehrenbach, S., Schnebelen, A., Frébourg, T., and Flori, E. (2009). Genetic compensation in a human genomic disorder. N. Engl. J. Med. 360, 1211-1216.
45. Alkalay, A.A., Guo, T., Montagna, C., Digilio, M.C., Dallapiccola, B., Marino, B., Morrow, B. (2011). Genetic dosage compensation in a family with velo-cardio-facial/DiGeorge/22q11.2 deletion syndrome. Am. J. Med. Genet. A 155, 548-554.
46. Weinzimer, S.A. (2001). Endocrine aspects of the 22q11.1 deletion. Genet. Med. 3, 19-22.
47. Nagasaki, K., Iwasaki, Y., Ogawa, Y., Kikuchi, T., and Uchiyama, M. (2011). Evaluation of parathyroid gland function using sodium bicarbonate infusion test for 22q11.2 deletion syndrome. Horm. Res. Paediatr. 75, 14-18.
48. Jatana, V., Gillis, J., Webster, B.H., and Adès, L.C. (2007). Deletion 22q11.2 syndrome--implications for the intensive care physician. Pediatr. Crit. Care Med. 8, 459-463.
49. Lima, K., Abrahamsen, T.G., Wolff, A.S., Husebye, E., Alimohammadi ,M., Kampe, O., Følling, I. (2011). Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. Eur. J. Endocrinol. 165, 345-352.
50. Meek, C.L., Kaplan. F., Pereira, R.S., Viljoen, A. (2011). Hypocalcemia following treatment for hyperthyroidism. Clin. Chem. 57, 811-814.
51. Daw, S. C., Taylor, C., Kraman, M., Call, K., Mao, J., Schuffenhauer, S., Meitinger, T., Lipson, T., Goodship, J., and Scambler, P. (1996). A common region of 10p deleted in DiGeorge and velocardiofacial syndromes. Nat. Genet. 13, 458-460.
52. Gottlieb, S., Driscoll, D. A., Punnett, H. H., Sellinger, B., Emanuel, B. S., and Budarf, M. L. (1998). Characterization of 10p deletions suggests two nonoverlapping regions contribute to the DiGeorge syndrome phenotype. Am. J. Hum. Genet. 62, 495-498.
53. Barakat, A. Y., D'Albora, J. B., Martin, M. M., and Jose, P. A. (1977). Familial nephrosis, nerve deafness, and hypoparathyroidism. J. Pediatr. 91, 61-64.
54. Bilous, R. W., Murty, G., Parkinson, D. B., Thakker, R. V., Coulthard, M. G., Burn, J., Mathias, D., and Kendall-Taylor, P. (1992). Autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. N. Engl. J. Med. 327, 1069-1074.
55. Schuffenhauer, S., Lichtner, P., Peykar-Derakhshandeh, P., Murken, J., Haas, O. A., Back, E., Wolff, G., Zabel, B., Barisic, I., Rauch, A., Borochowitz, Z., Dallapiccola, B., Ross, M., and Meitinger, T. (1998). Deletion mapping on chromosome 10p and definition of a critical region for the second DiGeorge syndrome locus (DGS2). Eur. J. Hum. Genet. 6, 213-225.
56. Van Esch, H., Groenen, P., Daw, S., Poffyn, A., Holvoet, M., Scambler, P., Fryns, J. P., Van den,WV., and Devriendt, K. (1999). Partial DiGeorge syndrome in two patients with a 10p rearrangement. Clin. Genet. 55, 269-276.
57. Lichtner, P., Konig, R., Hasegawa, T., Van Esch, H., Meitinger, T., and Schuffenhauer, S. (2000). An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14. J. Med. Genet. 37, 33-37.
58. Van Esch, H., Groenen, P., Nesbit, M. A., Schuffenhauer, S., Lichtner, P., Vanderlinden, G., Harding, B., Beetz, R., Bilous, R. W., Holdaway, I., Shaw, N. J., Fryns, J. P., Van de Ven, W., Thakker, R. V., and Devriendt, K. (2000). GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406, 419-422.
59. Nesbit, M. A., Bowl, M. R., Harding, B., Ali,A., Ayala, A., Crowe, C., et al. (2004). Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J. Biol. Chem. 279, 22624-22634.
60. Zahirieh, A., Nesbit, M.A., Ali, A., Wang, K., He, N., Stangou, M., Bamichas, G., Sombolos, K., Thakker, R.V., and Pei, Y. (2005). Functional analysis of a novel GATA3 mutation in a family with the hypoparathyroidism, deafness, and renal dysplasia syndrome. J. Clin. Endocrinol. Metab. 90, 2445-2450.
61. Ali, A., Christie, P.T., Grigorieva, I.V., et al. (2007). Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanism of DNA binding by the GATA3 transcription factor. Hum. Mol. Genet. 16, 265-275.
62. Grigorieva, I.V., Mirczuk, S., Gaynor, K.U., et al. (2010). Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J. Clin. Invest. 120, 2144-2155.
63. Kenny, F. M., and Linarelli, L. (1966). Dwarfism and cortical thickening of tubular bones. Transient hypocalcemia in a mother and son. Am. J. Dis. Child. 111, 201-207.
64. Caffey, J. (1967). Congenital stenosis of medullary spaces in tubular bones and calvaria in two proportionate dwarfs--mother and son; coupled with transitory hypocalcemic tetany. Am. J. Roentgenol. Radium. Ther. Nucl. Med. 100, 1-11.
65. Teebi, A. S. (2000). Hypoparathyroidism, retarded growth and development, and dysmorphism or Sanjad-Sakati syndrome: an Arab disease reminiscent of Kenny-Caffey syndrome. J. Med. Genet. 37, 145.
66. Parvari, R., Hershkovitz, E., Kanis, A., Gorodischer, R., Shalitin, S., Sheffield, V. C., and Carmi, R. (1998). Homozygosity and linkage-disequilibrium mapping of the syndrome of congenital hypoparathyroidism, growth and mental retardation, and dysmorphism to a 1-cM interval on chromosome 1q42-43. Am. J. Hum. Genet. 63, 163-169.
67. HRD/Autosomal Recessive Kenny-Caffey Syndrome Consortium. (2002). Mutation of TBCE causes hypopaarathyroidism-returdation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat. Genet. 32, 448-45
68. Voloshin, O., Gocheva, Y., Gutnick, M., et al. (2010). Tubulin chaperone E binds microtubules and proteasomes and protects against misfolded protein stress. Cell. Mol. Life Sci. 67, 2025-2038.
69. Parvari, R., Diaz, G.A., and Hershkovitz. E. (2007). Parathyroid development and the role of tubulin chaperone E. Horm. Res. 67, 12-21.
70. Seneca, S., De Meirleir, L., De Schepper, J., Balduck, N., Jochmans, K., Liebaers, I., and Lissens, W. (1997). Pearson marrow pancreas syndrome: a molecular study and clinical management. Clin. Genet. 51, 338-342.
71. Tengan, C. H., Kiyomoto, B. H., Rocha, M. S., Tavares, V. L., Gabbai, A. A., and Moraes, C. T. (1998). Mitochondrial encephalomyopathy and hypoparathyroidism associated with a duplication and a deletion of mitochondrial deoxyribonucleic acid. J. Clin. Endocrinol. Metab 83, 125-129.
72. Wilichowski, E., Gruters, A., Kruse, K., Rating, D., Beetz, R., Korenke, G. C., Ernst, B. P., Christen, H. J., and Hanefeld, F. (1997). Hypoparathyroidism and deafness associated with pleioplasmic large scale rearrangements of the mitochondrial DNA: a clinical and molecular genetic study of four children with Kearns-Sayre syndrome. Pediatr. Res. 41, 193-200.
73. Tyni, T., Rapola, J., Palotie, A., and Pihko, H. (1997). Hypoparathyroidism in a patient with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency caused by the G1528C mutation. J. Pediatr. 131, 766-768.
74. Brown, E.M. (2009). Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol. Metab. Clin. North. Am. 38, 437-445.
75. Alimohammadi, M., Björklund, P., Hallgren, A., Pöntynen, N., Szinnai, G., Shikama, N., Keller, M.P., Ekwall, O., Kinkel, S.A., Husebye, E.S., Gustafsson, J., Rorsman, F., Peltonen, L., Betterle, C., Perheentupa, J., Akerström, G., Westin, G., Scott, H.S., Holländer, G.A., and Kämpe, O. (2008). Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Engl. J. Med. 358, 1018-1028.
76. Eisenbarth, G. S., and Gottlieb, P. A. (2004). Autoimmune polyendocrine syndromes. New Engl. J. Med. 350, 2068-2079.
77. Li, Y., Song, Y. H., Rais, N., Connor, E., Schatz, D., Muir, A., and Maclaren, N. (1996). Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J. Clin. Invest. 97, 910-914.
78. Goswami, R., Brown, E. M., Kochupillai, N., Gupta, N., Rani, R., Kifor, O., Chattopadhyay N. (2004). Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150, 9-18.
79. Soderbergh, A., Myhre, A.G., Ekwall, O., Gebre-Medhin, G., Hedstrand, H., Landgren, E., et al. (2004). Prevalence and clinical associations in 10 defined autoantibodies in autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 89, 557-562.
80. Gylling, M., Kaariainen, E., Vaisanen, R., Kerosuo, L., Solin, M-L., Halme, L., Saari, S., Halonen, M., Kampe, O., Perheentupa, J., and Miettinene., A. (2003) The hypoparathyroidism of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: protective effect of male sex. J. Clin. Endocrinol. Metab. 88, 4602-4608.
81. Kemp, E.H., Gavalas, N.G., Krohn, K.J., Brown, E.M., Watson, P.F., Weetman, A.P.. (2009). Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 94, 4749-4756.
82. Mayer, A., Ploix, C., Orgiazzi, J., Desbos, A., Moreira, A., Vidal, H., Monier, J-C., Bienvenu, J., and Fabien, N. (2004). Calcium-sensing receptor autoantibodies are relevant makers of acquired hypoparathyroidism. J. Clin. Endocrinol. Metab. 89, 4484-4488.
83. Eisenbarth, G. S., and Gottlieb, P. A. (2004). Hypoparathyroidism and autoimmune polyendocrine syndromes. New Engl. J. Med. 351, 1032-1033.
84. Kifor, O., McElduff, A., LeBoff. M.S., et al. (2004). Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J. Clin. Endocrinol. Metab. 89, 548-556.
85. Buzi, F., Badolato, R., Mazza, C., Giliani, S., Notarangelo, L. D., Radetti, G., Plebani, A., and Notarangelo, L. D. (2003). Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: Time to review diagnostic criteria? J. Clin. Endocrinol. Metab. 88, 3146-3148.
86. Finnish-German APECED Consortium (1997). An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17, 399-403.
87. Nagamine, K., Peterson, P., Scott, H. S., Kudoh, J., Minoshima, S., Heino, M., Krohn, K. J., Lalioti, M. D., Mullis, P. E., Antonarakis, S. E., Kawasaki, K., Asakawa, S., Ito, F., and Shimizu, N. (1997). Positional cloning of the APECED gene. Nat. Genet. 17, 393-398.
88. Halonen, M., Kangas, H., Ruppell, T., Ilmarinen, T., Ollila, J., Kolmer, M., Vihinen, M., Palvimo, J., Saarela, J., Ulmanen, I., and Eskelin, P. (2004). APECED-causing mutations in AIRE reveal the functional domains of the protein. Hum. Mutat. 23, 245-257.
89. Akirav, E.M., Ruddle, N.H., and Herold KC. (2011). The role of AIRE in human autoimmune disease.  Nat Rev Endocrinol. 7, 25-33.
90. Cervato, S., Mariniello, B., Lazzarotto, F., Morlin, L., Zanchetta, R., Radetti, G., De Luca, F., Valenzise, M., Giordano, R., Rizzo, D., Giordano, C., and Betterle, C. (2009). Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin. Endocrinol. (Oxf). 70, 421-428.
91. Cheng, M.H., Fan, U., Grewal, N., Barnes, M., Mehta, A., Taylor, S., Husebye, E.S., Murphy, E.J., and Anderson, M.S. (2010). Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. N. Engl. J. Med. 362, 764-766.
92. Wilson, L. C., and Trembath, R. C. (1994). Albright's hereditary osteodystrophy. J. Med. Genet. 31, 779-784.
93. Levine, M. A. (1999). Pseudohypoparathyroidism: from bedside to bench and back. J. Bone Miner. Res. 14, 1255-1260.
94. Levine, M. A. (2000). The molecular basis for parathyroid hormone resistance in pseudohypoparathyroidism. In "The Genetics of Osteoporosis and Metabolic Bone Disease", (Econs, M.J. ed.), pp.179-209. Humana Press, Totawa NJ.
95. Spiegel, A. M. and Weinstein, L. S. (2001). Pseudohypoparathyroidism. In "The Metabolic and Molecular Bases of Inherited Disease", 8th ed. (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D. eds.), pp.4205-4221. McGraw-Hill, New York.
96. Chase, L.R., Melson, G.L., and Aurbach, G.D. (1969) Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J. Clin. Invest. 48, 1832-1844
97. Albright, F., Burnett, C. H., and Smith, P. H. (1942). Pseudohypoparathyroidism: An example of 'Seabright-Bantam syndrome'. Endocrinol. 30, 922-932.
98. De Sanctis, L., Vai, S., Andreo, M.R., et al. (2004). Brachydactyly in 14 genetically characterized pseudohypoparathyroid type 1a patients. J. Clin. Endocrinol. Metab. 89, 1650–1655.
99. Puzhko, S., Goodyer, C.G., Kerachian, M.A., Canaff, L., Misra, M., Jüppner, H., Bastepe, M., and Hendy, G.N. (2011) Parathyroid hormone signaling via Gas is selectively inhibited by an NH2-terminally truncated Gas: implications for pseudohypoparathyroidism. J. Bone Miner. Res. Epub ahead of print
100. Poznanski, A.K., Werder, E.A., Giedion, A., Martin, A., Shaw, H. (1977). The pattern of shortening of the bones of the hand in PHP and PPHP--A comparison with brachydactyly E, Turner Syndrome, and acrodysostosis. Radiology 123, 707-718.
101. Brickman, A. S., Stern, N., and Sowers, J. R. (1988). Hypertension in pseudohypoparathyroidism type I. Am. J. Med. 85, 785-792.
102. Koch, T., Lehnhardt, E., Bottinger, H., Pfeuffer, T., Palm, D., Fischer, B., Radeke, H., and Hesch, R. D. (1990). Sensorineural hearing loss owing to deficient G proteins in patients with pseudohypoparathyroidism: results of a multicentre study. Eur. J. Clin. Invest. 20, 416-421.
103. Goadsby, P. J., Lollin, Y., and Kocen, R. S. (1991). Pseudopseudohypoparathyroidism and spinal cord compression. J Neurol. Neurosurg. Psychiatry 54, 929-931.
104. Maeda, S.S., Fortes, E.M., Oliveira, U.M., Borba, V.C., and Lazaretti-Castro, M. (2006). Hypoparathyroidism and pseudohypoparathyroidism. Arq. Bras. Endocrinol. Metab. 50, 664-673.
105. Ong, K. K., Amin, R., and Dunger, D. B. (2000). Pseudohypoparathyroidism--another monogenic obesity syndrome. Clin. Endocrinol. (Oxf) 52, 389-391.
106. Chen, M., Wang, J., Dickerson, K.E., et al. (2009). Central nervous system imprinting of the G protein G(s) alpha and its role in metabolic regulation. Cell Metab. 9, 548-555.
107. Phelan, M. C., Rogers, R. C., Clarkson, K. B., Bowyer, F. P., Levine, M. A., Estabrooks, L. L., Severson, M. C., and Dobyns, W. B. (1995). Albright hereditary osteodystrophy and del(2) (q37.3) in four unrelated individuals. Am. J. Med. Genet. 58, 1-7.
108. Williams, S.R., Aldred, M.A., Der Kaloustian, V.M., et al. (2010). Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachdactyly type E, developmental delays, and behavioral problems. Am. J. Hum. Genet. 87, 219-228.
109. Johnson, D., Kan, S.H., Oldridge, M., et al (2003). Missense mutations in the homeodomain of HOX13 are associated with brachydactyly type D and E. Am. J. Hum. Genet. 72, 984-997.
110. Maass, P.G., Wirth, J., Aydin, A., et al. (2010). A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to brachydactyly type E. Hum. Mol. Genet. 19, 848-860.
111. Klopocki, E., Hennig, B.P., and Dathe, K., et al. (2010). Deletion and point mutations of PTHLH cause brachydactyly type E. Am. J. Hum. Genet. 86, 434-439.
112. Farfel, Z., Brickman, A. S., Kaslow, H. R., Brothers, V. M., and Bourne, H. R. (1980). Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N. Engl. J. Med. 303, 237-242.
113. Levine, M. A., Downs, R. W., Jr., Singer, M., Marx, S. J., Aurbach, G. D., and Spiegel, A. M. (1980). Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem. Biophys. Res. Commun. 94, 1319-1324.
114. Levine, M. A., Jap, T. S., Mauseth, R. S., Downs, R. W., and Spiegel, A. M. (1986). Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine, and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. J. Clin. Endocrinol. Metab 62, 497-502.
115. Beaudet, A. L. (2004). Complex imprinting. Nat. Genet. 36:793-5.
116. Yu, S., Yu, D., Lee, E., Eckhaus, M., Lee, R., Corria, Z., Accili, D., Westphal, H., and Weinstein, L.S. (1998). Variable and tissue-specific hormone resistance in heterotrimeric Gs protein α-subunit (Gsα) knockout mice is due to tissue-specific imprinting of the Gsα gene. Proc. Natl. Acad. Sci. USA 95, 8715-8720.
117. Hayward, B., Barlier, A., Korbonits, M., Grossman, A., Jacquet, P., Enjalbert, A., and Bonthron, D. (2001). Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J. Clin. Invest. 107, R31-36
118. Mantovani, G., Ballare, E., Giammona, E., Beck-Peccoz, P., and Spada, A. (2002). The Gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J. Clin. Endocrinol. Metab. 87, 4736-4740.
119. Germain-Lee, E.L., Ding, C.L., Deng, Z., Crane, J.L., Saji, M., Ringel, M.D., and Levine, M.A. (2002). Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem. Biophys. Res. Commun. 296, 67-72.
120. Davies, S. J., and Hughes, H. E. (1993). Imprinting in Albright's hereditary osteodystrophy. J Med. Genet. 30, 101-103.
121. Liu, J., Litman, D., Rosenberg, M. J., Yu, S., Biesecker, L. G., and Weinstein, L. S. (2000). A GNAS imprinting defect in pseudohypoparathyroidism type IB. J Clin. Invest 106, 1167-1174.
122. Zheng, H., Radeva, G., McCann, J. A., Hendy, G. N., and Goodyer, C. G. (2001). Galphas transcripts are biallelically expressed in the human kidney cortex: implications for pseudohypoparathyroidism type 1b. J Clin. Endocrinol. Metab 86, 4627-4629.
123. Weinstein, L. S., Yu, S., and Ecelbarger, C. A. (2000). Variable imprinting of the heterotrimeric G protein G(s) alpha-subunit within different segments of the nephron. Am. J Physiol Renal Physiol 278, F507-F514.
124. Weinstein, L. S., Yu, S., Warner, D. R., and Liu, J. (2001). Endocrine manifestations of stimulatory G-protein alpha-subunit mutations and the role of genomic imprinting. Endocr. Rev. 22, 675-705.
125. Weinstein, L. S., Liu, J., Sakamoto, A., Xie, T., and Chen, M. (2004). Minireview: GNAS: normal and abnormal functions. Endocrinology. 145, 5459-5464.
126. Levine, M. A., Ahn, T. G., Klupt, S. F., Kaufman, K. D., Smallwood, P. M., Bourne, H. R., Sullivan, K. A., and Van Dop, C. (1988). Genetic deficiency of the alpha subunit of the guanine nucleotide- binding protein Gs as the molecular basis for Albright hereditary osteodystrophy. Proc. Natl. Acad. Sci. U. S. A 85, 617-621.
127. Patten, J. L., Johns, D. R., Valle, D., Eil, C., Gruppuso, P. A., Steele, G., Smallwood, P. M., and Levine, M. A. (1990). Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N. Engl. J Med. 322, 1412-1419.
128. Weinstein, L. S., Gejman, P. V., Friedman, E., Kadowaki, T., Collins, R. M., Gershon, E. S., and Spiegel, A. M. (1990). Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc. Natl. Acad. Sci. U. S. A 87, 8287-8290.
129. Aldred, M. A., and Trembath, R. C. (2000). Activating and inactivating mutations in the human GNAS gene. Hum. Mutat. 16, 183-189.
130. Ahrens, W., Hiort, O., Staedt, P., Kirschner, T., Marschke, C., and Kruse, K. (2001). Analysis of the GNAS gene in Albright's hereditary osteodystrophy. J Clin. Endocrinol. Metab 86, 4630-4634.
131. Aldred, M. A., Bagshaw, R. J., Macdermot, K., Casson, D., Murch, S. H., Walker-Smith, J. A., and Trembath, R. C. (2000). Germline mosaicism for a GNAS mutation and Albright hereditary osteodystrophy. J Med. Genet. 37, E35.
132. De Nanclares, G.P., Fernandez-Rebollo, E., Santin, I., Garcia-Cuartero, B., Gaztambide, S., Menendez, E., Morales, M.J., Pombo, M., Bilbao, J.R., Barros, F., Zazo, N., Ahrens, W., Jüppner, H., Hiort, O., Castano, L., and Bastepe, M. (2007) Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 92:2370-2373.
133. Fernandez-Rebollo, E., Garcia-Cuartero, B., Garin, I., Largo, C., Martinez, F., Garcia-Lacalle, C., Castano, L., Bastepe, M., and Perez de Nanclares, G. (2010) Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab 95:765-771.
134. Namnoum, A. B., Merriam, G. R., Moses, A. M., and Levine, M. A. (1998). Reproductive dysfunction in women with Albright's hereditary osteodystrophy. J Clin. Endocrinol. Metab 83, 824-829.
135. McIlroy, J., Dryburgh, F., Hinnie, J., Dargie, R., and Al Rawi, A. (1999). Oestrogen and calcium homeostasis in women with hypoparathyroidism. BMJ 319, 1252-1253.
136. Breslau, N. A., and Zerwekh, J. E. (1986). Relationship of estrogen and pregnancy to calcium homeostasis in pseudohypoparathyroidism. J Clin. Endocrinol. Metab 62, 45-51.
137. Germain-Lee, E. L., Groman, J., Crane, J. L., Jan de Beur, S. M., and Levine, M. A. (2003). Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J. Clin. Endocrinol. Metab. 88, 4059-4069.
138. Mantovani, G., Maghnie, M., Weber, G., De Menis, E., Brunelli, V., Cappa, M., Loli, P., Beck-Peccoz, P., and Spada, A. (2003). Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs alpha gene. J. Clin. Endocrinol. Metab. 88, 4070-4074.
139. Mantovani, G., Ferrante, E., Giavoli, C. Linglart, A., Cappa, M., Cisternino, M., Maghnie, M., Ghizzoni, L., de Sanctis, L., Lania, A.G., Beck-Peccoz, P., and Spada, A. (2010) Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: first study on the effect on growth. J. Clin .Endocrinol. Metab. 95, 5011-5017
140. Liu, J., Erlichman, B., and Weinstein, L.S. (2003) The stimulatory G protein α-subunit Gsα is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J. Clin. Endocrinol. Metabol. 88, 4336-4341
141. Long, D.N., McGuire, S., Levine, M.A., Weinstein, L.S., and Germain-Lee, E.L. (2007). Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J. Clin. Endocrinol. Metab. 92, 1073-1079.
142. Mantovani, G., Bondioni, S., Locatelli, M., Pedroni, C., Lania, A.G., Ferrante, E., Filopanti, M., Beck-Peccoz, P., and Spada, A. (2004) Biallelic expression of the Gsalpha gene in human bone and adipose tissue. J. Clin. Endocrinol. Metab. 89:6316-6319.
143. Chen, M., Wang, J., Dickerson, K.E., Kelleher, J., Xie, T., Gupta, D., Lai ,E.W., Pacak, K., Gavrilova, O., Weinstein, L.S. (2009) Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab. 9, 548-555.
144. Mouallem, M., Shaharabany, M., Weintrob, N., Shalitin, S., Nagelberg, N., Shapira, H., Zadik, Z., Farfel, Z. (2008). Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin. Endocrinol. (Oxf) 68, 233-239.
145. Murray, T. M., Rao, L. G., Wong, M. M., Waddell, J. P., McBroom, R., Tam, C. S., Rosen, F., and Levine, M. A. (1993). Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J. Bone Miner. Res. 8, 83-91.
146. Ish-Shalom, S., Rao, L. G., Levine, M. A., Fraser, D., Kooh, S. W., Josse, R. G., McBroom, R., Wong, M. M., and Murray, T. M. (1996). Normal parathyroid hormone responsiveness of bone-derived cells from a patient with pseudohypoparathyroidism. J. Bone Miner. Res. 11, 8-14.
147. Laspa, E., Bastepe, M., Jüppner, H., and Tsatsoulis, A. (2004). Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance. J Clin Endocrinol Metab. 89, 5942-5947.
148. Unluturk, U., Harmanci, A., Babaoglu, M., Yasar, U., Varli, K., Bastepe, M., and Bayraktar, M. (2008). Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid. Am. J. Med. Sci. 336, 84-90.
149. Schipani, E., Weinstein, L. S., Bergwitz, C., Iida-Klein, A., Kong, X. F., Stuhrmann, M., Kruse, K., Whyte, M. P., Murray, T., Schmidtke, J., van Dop, C., Brickman, A.S., Crawford, J.D., Potts, J.T. Jr., Kronenberg, H.M., Abou-Samra, A.B., Segre, G.V., and Jüppner, H. (1995). Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin. Endocrinol. Metab. 80, 1611-1621.
150. Fukumoto, S., Suzawa, M., Takeuchi, Y., Kodama, Y., Nakayama, K., Ogata, E., Matsumoto, T., and Fujita, T. (1996). Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. J Clin. Endocrinol. Metab. 81, 2554-2558.
151. Bettoun, J. D., Minagawa, M., Kwan, M. Y., Lee, H. S., Yasuda, T., Hendy, G. N., Goltzman, D., and White, J. H. (1997). Cloning and characterization of the promoter regions of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene: analysis of deoxyribonucleic acid from normal subjects and patients with pseudohypoparathyroidism type 1b. J Clin. Endocrinol. Metab. 82, 1031-1040.
152. Juppner, H., Schipani, E., Bastepe, M., Cole, D. E.C., Lawson, M. L., Mannstadt, M., Hendy, G. N., Plotkin, H., Koshiyama, H., Koh, T., Crawford, J. D., Olsen, B. R., and Vikkula, M. (1998). The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc. Natl. Acad. Sci. U. S. A 95, 11798-11803.
153. Jan de Beur, S. M., Ding, C. L., LaBuda, M. C., Usdin, T. B., and Levine, M. A. (2000). Pseudohypoparathyroidism 1b: exclusion of parathyroid hormone and its receptors as candidate disease genes. J Clin. Endocrinol. Metab 85, 2239-2246.
154. Bastepe, M., Pincus, J. E., Sugimoto, T., Tojo, K., Kanatani, M., Azuma, Y., Kruse, K., Rosenbloom, A. L., Koshiyama, H., and Juppner, H. (2001). Positional dissociation between the genetic mutation responsible for pseudohypoparathyroidism type Ib and the associated methylation defect at exon A/B: evidence for a long-range regulatory element within the imprinted GNAS locus. Hum. Mol. Genet. 10, 1231-1241.
155. Bastepe, M., Frohlich, L. F., Hendy, G. N., Indridason, O. S., Josse, R. G., Koshiyama, H., Korkko, J., Nakamoto, J. M., Rosenbloom, A. L., Slyper, A. H., Sugimoto, T., Tsatsoulis, A., Crawford, J. D., and Juppner. H. (2003). Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J. Clin. Invest. 112, 1255-1263.
156. Linglart, A., Gensure, R.C., Olney, R.C., Jüppner, H., and Bastepe, M. (2005). A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am. J. Hum. Genet. 76, 804-814.
157. Bastepe, M., Frohlich, L. F., Linglart, A., Abu-Zahra, H. S., Tojo, K., Ward, L. M., and Juppner, H. (2005). Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat. Genet. 37, 25-27.
158. Chillambhi, S., Turan, S., Hwang, D.Y., Chen, H.C., Jüppner, H., and Bastepe, M. (2010). Deletion of the noncoding GNAS antisense transcript causes pseudohypoparathyroidism type Ib and biparental defects of GNAS methylation in cis. J. Clin. Endocrinol. Metab. 95, 3993-4002.
159. Bastepe, M., Lane, A. H., and Juppner, H. (2001). Paternal uniparental isodisomy of chromosome 20q--and the resulting changes in GNAS methylation--as a plausible cause of pseudohypoparathyroidism. Am. J Hum. Genet. 68, 1283-1289.
160. Lecumberri, B., Fernandez-Rebollo, E., Sentchordi, L., Saavedra, P., Bernal-Chico, A., Pallardo, L.F., Bustos, J.M., Castano, L., De Santiago, M., Hiort, O., de Nanclares, G.P., and Bastepe, M. (2010). Coexistence of two different pseudohypoparathyroidism subtypes (Ia and Ib) in the same kindred with independent Gs{alpha} coding mutations and GNAS imprinting defects. J. Med. Genet. 47, 276-280.
161. Fernandez-Rebollo, E., Lecumberri, B., Garin, I., Arroyo, J., Bernal-Chico, A., Goni, F., Orduna, R., Spanish PHP Group, Castano, L., de Nanclares, G.P. (2010). New mechanisms involved in paternal 20q disomy associated with pseudohypoparathyroidism. Eur. J. Endocrinol. 163, 953-962.
162. Bastepe, M., Altug-Teber, O., Agarwal, C., Oberfield, S.E., Bonin, M., and Jüppner, H. (2011). Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone 48, 659-662.
163. Linglart, A., Bastepe, M., and Jüppner, H. (2007). Similar clinical and laboratory findings in patients with symptomatic autosomal dominant and sporadic pseudohypoparathyroidism type Ib despite different epigenetic changes at the GNAS locus. Clin. Endocrinol. (Oxf) 67, 822-831.
164. De Nanclares, G.P., Fernandez-Rebollo, E., Santin, L., et al. (2007). Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright’s hereditary osteodystrophy. J. Clin. Endocrinol. Metab. 92, 2370-2373.
165. Mariot, V., Maupetit-Mehouas, S., Sinding, C., Kottler, M.L., and Linglart, A. (2008) A maternal epimutation of GNAS leads to Albright osteodystrophy and parathyroid hormone resistance. J. Clin. Endocrinol. Metab. 93, 661-665.
166. Mantovani, G., de Sanctis, L., Barbieri, A.M., Elli, F.M., Bollati, V., Vaira, V., Labarile, P., Bondioni, S., Peverelli, E., Lania, A.G., Beck-Peccoz, P., and Spada, A. (2010). Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of Albright hereditary osteodystrophy and molecular analysis in 40 patients. J. Clin. Endocrinol. Metab. 95, 651-658.
167. Wu, W. I., Schwindinger, W. F., Aparicio, L. F., and Levine, M. A. (2001). Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s). A cause of pseudohypoparathyroidism type Ib. J. Biol. Chem. 276, 165-171.
168. Linglart, A., Carel, J. C., Garabedian, M., Le, T., Mallet, E., and Kottler, M. L. (2002). GNAS lesions in pseudohypoparathyroidism Ia and Ic: genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J. Clin. Endocrinol. Metab. 87, 189-197.
169. Linglart A., Mahon, M.J., Kerachian, M.A., Berlach, D.M., Hendy, G.N., Jüppner, H., and Bastepe, M. (2006). Coding GNAS mutations leading to hormone resistance impair in vitro agonist- and cholera toxin-induced adenosine cyclic 3',5'-monophosphate formation mediated by human XLαs. Endocrinology 147, 2253-2262.
170. Linglart, A., Carel, J.C., Garabedian, M., Le, T., Mallet, E., and Kottler, M.L. (2002). GNAS1 esions in pseudohypoparathyroidism Ia and Ic: Genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J. Clin. Endocrinol. Metab. 87, 189-97
171. Thiele, S., De Sanctis, L., Werner, R., et al. (2011). Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type 1c defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsalpha-receptor interaction. Hum. Mutat. 32, 653-660
172. Drezner, M., Neelon, F. A., and Lebovitz, H. E. (1973). Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N. Engl. J. Med. 289, 1056-1060.
173. Linglart, A., Menguy, C., Couvineau, A., et al. (2011). Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N. Engl. J. Med. 364, 2218-2226.
174. Weinstein, L.S. (2000). Fibrous dysplasia and the McCune-Albright syndrome. In "The Genetics of Osteoporosis and Metabolic Bone Disease", (Econs, M. J.ed.), pp.163-177. Humana Press, Totawa NJ
175. Weinstein, L.S., and Collins, M.T. (2008). Diseases resulting from defects in the G protein Gsa. In Bilezikian, J.P., Martin, T.J., Raisz, L.G. (eds): Principles of Bone Biology. 3rd ed. Academic Press, San Diego, pp 1453-1477.
176. Cole, D.E.C., Fraser, F.C., Glorieux, F.H., Jequier, S., Marie, P.J., Reade, T.M., and Scriver, C.R. (1983). Panostotic fibrous dysplasia: a congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. Am. J. Med. Genet. 14, 725-735.
177. Cole, D.E.C., and Whyte, M.P. (1997). Hyperphosphatasia Syndromes. In "Studies in Stomatology and Craniofacial Biology", (Cohen, M. M., Jr., and Baum, B. J.eds.), pp.245-272. IOS Press, Amsterdam.
178. Landis, C.A., Masters, S.B., Spada, A., Pace, A.M., Bourne, H.R., Vallar, L. (1989). GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340, 692-696.
179. Iiri, T., Herzmark, P., Nakamoto, J. M., Van Dop, C., and Bourne, H. R. (1994). Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature 371, 164-168.
180. Makita, N., Sato, J., Rondard, P., Fukamachi, H., Yuasa, Y., Aldred, M.A., Hashimoto, M., Fujita, T., Iiri, T. (2007). Human G(salpha) mutant causes pseudohypoparathyroidism type Ia/neonatal diarrhea, a potential cell-specific role of the palmitoylation cycle. Proc. Natl. Acad. Sci. USA 104, 17424-17429.
181. Eddy, M. C., De Beur, S. M., Yandow, S. M., McAlister, W. H., Shore, E. M., Kaplan, F. S., Whyte, M. P., and Levine, M. A. (2000). Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner. Res. 15, 2074-2083.
182. Kaplan, F. S., and Shore, E. M. (2000). Progressive osseous heteroplasia. J. Bone Miner. Res. 15, 2084-2094.
183. Yeh, G. L., Mathur, S., Wivel, A., Li, M., Gannon, F. H., Ulied, A., Audi, L., Olmstead, E. A., Kaplan, F. S., and Shore, E. M. (2000). GNAS mutation and Cbfa1 misexpression in a child with severe congenital platelike osteoma cutis. J Bone Miner. Res. 15, 2063-2073.
184. Shore, E.M., and Kaplan, F.S. (2010). Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 6, 518-527.
185. Adegbite, N.S., Xu, M., Kaplan, F.S., Shore, E.M., and Pignolo, R.J. (2008). Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am. J. Med. Genet. A. 146A, 1788-1796.
186. Shore, E.M., Ahn, J., Jan de Beur, S. et al. (2002). Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N. Engl. J. Med. 346, 99-106.
187. Gardella, T. J., and Juppner H. (2000). Interaction of PTH and PTHrP with their receptors. Rev. Endocr. Metab. Disord. 1, 317-329.
188. Scillitani, A., Jang, C., Wong, B.Y-L., Hendy, G.N., and Cole, D.E.C. (2006). A functional polymorphism in PTHR1 promoter region is associated with adult height and BMD measured at the femoral neck in a large cohort of young caucasian women. Hum. Genet. 119, 416-421.
189. Jüppner, H., Schipani, E., and Silve, C. (2008) Genetic disorders caused by PTH/PTHrP receptor mutations. In Bilezikian, J.P., Martin, T.J., Raisz, L.G. (eds): Principles of Bone Biology. 3rd ed. Academic Press, San Diego, pp 1431-1452.
190. Blomstrand, S., Claesson, I., and Save-Soderbergh, J. (1985). A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediatr. Radiol. 15, 141-143.
191. Loshkajian, A., Roume, J., Stanescu, V., Delezoide, A.-L., Stampf, F., and Maroteaux, P. (1997). Familial Blomstrand chondrodysplasia with advanced skeletal maturation: Further delineation. Am. J. Med. Genet. 71, 283-288.
192. Zhang, P., Jobert, A. S., Couvineau, A., and Silve, C. (1998). A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin. Endocrinol. Metab 83, 3365-3368.
193. Karperien, M., van der Harten, H. J., van Schooten, R., Farih-Sips, H., den Hollander, N. S., Kneppers, S. L., Nijweide, P., Papapoulos, S. E., and Lowik, C. W. (1999). A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH- related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J Clin. Endocrinol. Metab. 84, 3713-3720.
194. Karaplis, A.C., He, B., Nguyen M.T., Young, I.D., Semeraro, D., Ozawa, H., and Amizuka, N. (1998). Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 139, 5255-5258.
195. Oostra, R.J., van der Harten, J.J., Rijnders, W.P., Scott, R.J., Young, M.P., and Trump, D. (2000). Blomstrand osteochondrodysplasia: three novel cases and histological evidence for heterogeneity. Virchows Arch. 436, 28-35.
196. Hoogendam, J., Farih-Sips, H., Wynaendts, L.C., Lowik, C.W., Wit, J.M., Karperien, M. (2007). Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing Blomstrand osteochondrodysplasia types I and II. J. Clin. Endocrinol. Metab. 92, 1088-1095.
197. Duchatelet, S., Ostergaard, E., Cores, D., Lemainque, A., and Julier, C., (2005). Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum. Mol. Genet. 14, 1-5.
198. Hopyan, S., Gokgoz, N., Poon, R., Gensure, R. C., Yu, C., Cole, W. G., Bell, R.S., Juppner, H., Andrulis, I.L., Wunder, J.S., and Alman, B. A. (2002). A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat. Genet. 30, 306-10.
199. Couvineau, A., Wouters, W., Bertrand, G., et al. (2008). PTHR1 mutations associated with Oilier disease result in receptor loss of function. Hum. Mol. Genet. 17, 2766-2775.
200. Rozeman, L. B., Sangiorgi, L., Briaire-de Bruijn, I. H., Mainil-Varlet, P., and Bertoni, F., Cleton-Jansen, A. M., Hogendoorn, P. C., and Bovee, J. V. (2004). Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum. Mutat. 24, 466-473.
201. Collinson, M., Leonard, S.J., Charlton, J., et al. (2010). Symmetrical enchondromatosis is associated with duplication of 12p11.23 to 12p11.22 including PTHLH. Am. J. Med. Genet. Part A. 152A, 3124-3128.
202. Decker, E., Stellzig-Eisenhauer, A., Fiebig, B.S., et al. (2008) PTHR1 loss-of function mutations in familial, non-syndromic primary failure of tooth eruption. Am. J. Hum. Genet. 83, 781-786.
203. Frazier-Bowers, S.A., Simmons, D., Wright, J.T., Proffit, W.R., and Ackerman, J.L. (2010). Primary failure of eruption and PTH1R: The importance of a genetic diagnosis for orthodontic treatment planning. Am. J. Orthod. Dentofacial. Orthop. 137, 160.e1-160.e7.
204. Konrad, M., Schlingmann, K. P., and Gudermann, T. (2004). Insights into the molecular nature of magnesium homeostasis. Am. J. Physiol. Renal Physiol. 286, F599-F605.
205. Mittendorf, E. A., Merlino, J. I., and McHenry, C. R. (2004). Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am. Surg. 70, 114-119.
206. Khan, M.I., Waguespack, S.G., Hu, M.I. (2011). Medical management of postsurgical hypoparathyroidism. Endocr. Pract. 17 Suppl 1, 18-25.
207. Arlt, W., Fremerey, C., Callies, F., Reincke, M., Schneider, P., Timmermann, W., and Allolio, B. (2002). Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146, 215-222.
208. Okano, K., Furukawa, Y., Morii, H., and Fujita, T. (1982). Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. J Clin. Endocrinol. Metab. 55, 238-243.
209. Winer, K. K., Ko, C. W., Reynolds, J. C., Dowdy, K., Keil, M., Peterson, D., Gerber, L. H., McGarvey. C, and Cutler, G. B. Jr. (2003). Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88, 4214-4220.
210. Winer, K.K., Sinaii, N., Peterson, D., Sainz, B. Jr., Cutler, and G.B. Jr. (2008). Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J. Clin. Endocrinol. Metab. 93, 3389-3395.
211. Winer, K.K, Sinaii, N., Reynolds, J., Peterson, D., Dowdy, K., and Cutler, G.B. Jr. (2010). Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680-2688.
212. Rubin, M.R., Sliney, J. Jr., McMahon, D.J., Silverberg, S.J., and Bilezikian, J.P. (2010). Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos. Int. 21, 1927-1934.
213. Rubin, M., Dempster, D., Sliney, J., Zhou, H., Nickolas, T., Stein, E., Dworakowski, E., Dellabadia, M., Ives, R., McMahon, D., Zhang, C., Silverberg, S., Shane, E., Cremers, S., and Bilezikian, J. (2011). PTH(1-84) administration reverses abnormal bone remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. [Epub ahead of print].
214. Jolette, J., Wilker, C.E., Smith, S.Y., Doyle, N., Hardisty, J.F., Metcalfe, A.J., Marriott, T.B., Fox, J., and Wells, D.S. (2006). Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol. 34, 929-940.
215. Mittelman, S.D., Hendy, G.N., Fefferman, R.A., Canaff, L., Mosesova, I., Cole, D.E.C., Burkett, L., and Geffner, M.E. (2006). A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone. J. Clin. Endocrinol. Metab. 91, 2474-2479.
216. Theman, T.A., Collins, M.T., Dempster, D.W., Zhou, H., Reynolds, J.C., Brahim, J.S., Roschger, P., Klaushofer, K., and Winer, K.K. (2009). PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J. Bone Miner. Res. 24, 964-973.
217. Sikjaer, T., Rejnmark, L., and Mosekilde, L. (2011). PTH treatment in hypoparathyroidism. Curr. Drug Saf. 6, 89-99.
218. Nemeth, E.F., Delmar, E. G., Heaton, W. L., Miller, M. A., Lambert, L. D., Conklin, R. L., Gowen, M., Gleason, J. G., Bhatnagar, P. K., and Fox, J. (2001). Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299, 323-331.
219. John, M.R., Widler, L., Gamse, R., Buhl, T., Seuwen, K., Breitenstein, W., Bruin, G.J, Belleli, R., Klickstein, L.B., and Kneissel, M. (2011). ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 49, 233-241.
220. Sato, K., Hasegawa, Y., Nakae, J., Nanao, K., Takahashi, I., Tajima, T., Shinohara, N., and Fujieda, K. (2002). Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 87,3068-3073.